Combiprasal® Nebuliser Solution
- COMBIPRASAL is indicated for the management of bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD) who require regular treatment with both ipratropium bromide and salbutamol.
- Cost effective than generic combination therapy with improved patient compliance
- Method of administration - Inhalation use only.
- Bioequivalent to the originator brand
- Available Strengths :0.5 mg / 2.5 mg Nebuliser Solution
- Pack Size :60 x 2.5ml Vials
- Dose :One single-dose container three or four times daily.
Ipratropium Bromide + Salbutamol cost effectiveness with COMBIPRASAL Nebuliser Solution
Visit EMC for more detail :